Top Story

Targeted fusion-guided biopsy improved detection of high-risk prostate cancers

January 27, 2015

Targeted magnetic resonance/ultrasound fusion prostate biopsy detected significantly more cases of high-risk prostate cancers than standard extended-sextant biopsy in men undergoing biopsy for suspected prostate cancer, according to study results.

“This study demonstrates that targeted fusion-guided biopsy could significantly enhance our ability to identify patients with high-risk prostate cancers that need more aggressive treatment,” researcher Mohummad Minhaj Siddiqui, MD, assistant professor of surgery at the University of Maryland School of Medicine and director of urologic robotic surgery at the University of Maryland Marlene and Stewart Greenebaum Cancer Center, said in a press release. “With fusion technology, we now have a tool to help us differentiate high-risk cancers from low-risk ones that may require minimal or no treatment. There is a concern that we over-diagnose and over-treat low-risk cancers that are unlikely to be terminal, and this technology enables us to make a more reliable diagnosis than the current standard practice.”

Stacey A. Kenfield, ScD In the JournalsPerspective

High-dose selenium supplementation may increase risk for prostate cancer mortality

January 22, 2015
Selenium supplements, especially in higher doses, may increase the risk for prostate cancer-related death if administered after diagnosis, according to the results of a…
Justin E. Bekelman, MD In the Journals

Radiation plus hormone therapy benefited older men with prostate cancer

January 21, 2015
The addition of radiation therapy to androgen deprivation therapy improved survival among elderly men with locally advanced prostate cancer, according to an…
Neha Vapiwala, MD In the Journals

Proton therapy, IMRT demonstrated similar toxicity profiles in prostate cancer

January 16, 2015
Patients with prostate cancer who underwent proton beam therapy experienced similar gastrointestinal and genitourinary side effects as those who underwent…
CME CNE
Low Risk AAMDS

Treatment Decision-Making through the Spectrum of MDS:
Case 1 Low Risk MDS

An educational presentation from Aplastic Anemia & MDS International Foundation.

MDS is a difficult disease to diagnose and treat. Frequently it is challenging for healthcare providers to explain MDS…
More »
CME CNE
Stem Cell Transplant for AAMDS

Treatment Decision-Making through the Spectrum of MDS:
Case 3 Stem Cell Transplant for MDS

An educational presentation from Aplastic Anemia & MDS International Foundation.

MDS is a difficult disease to diagnose and treat. Frequently it is challenging for healthcare providers to explain to…
More »
In the Journals

Targeted fusion-guided biopsy improved detection of high-risk prostate cancers

January 27, 2015
Targeted magnetic resonance/ultrasound fusion prostate biopsy detected significantly more cases of high-risk prostate cancers than standard…
Stacey A. Kenfield, ScD In the JournalsPerspective

High-dose selenium supplementation may increase risk for prostate cancer mortality

January 22, 2015
Selenium supplements, especially in higher doses, may increase the risk for prostate cancer-related death if administered after diagnosis, according…
Justin E. Bekelman, MD In the Journals

Radiation plus hormone therapy benefited older men with prostate cancer

January 21, 2015
The addition of radiation therapy to androgen deprivation therapy improved survival among elderly men with locally advanced prostate cancer…
Neha Vapiwala, MD In the Journals

Proton therapy, IMRT demonstrated similar toxicity profiles in prostate cancer

January 16, 2015
Patients with prostate cancer who underwent proton beam therapy experienced similar gastrointestinal and genitourinary side effects as those who…
Michael Schweizer In the Journals

Bipolar androgen therapy benefited men with prostate cancer and no symptoms

January 13, 2015
Testosterone has been found to suppress some advanced prostate cancers, countering previous beliefs that the hormone feeds the disease, according to…
Jai N. Patel, PharmD In the Journals

Bevacizumab not significantly associated with VTE risk in patients with prostate cancer

January 12, 2015
Bevacizumab was significantly associated with an increased risk for arterial thromboembolism among patients with prostate cancer but was not…
In the Journals

Active surveillance safe for favorable-risk prostate cancer

January 7, 2015
Active surveillance appeared safe and feasible for patients with favorable-risk prostate cancer, according to long-term follow-up of a prospective…
In the Journals

Bisphosphonate prescriptions low among men who underwent ADT

January 2, 2015
Although guidelines recommend bisphosphonates for men who initiate androgen deprivation therapy, prescriptions for these agents in this patient…
In the JournalsPerspective

Testosterone therapy did not increase prostate cancer risk in hypogonadal men

December 3, 2014
Hypogonadal men treated with testosterone therapy are not at increased risk for prostate cancer, according to research published in The Journal of
In the Journals

Olaparib induced tumor response in patients with germline BRCA1/BRCA2 mutations

December 1, 2014
Olaparib monotherapy induced responses across tumor types in patients with germline BRCA1 or BRCA2 mutations, according to results of a multicenter…
More Headlines »
morganatic-roan